Zynerba Pharmaceuticals, Inc. (ZYNE) Stock Analysis

Zynerba Pharmaceuticals, Inc. (ZYNE) Healthcare & Pipeline Overview

Zynerba Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in transdermal cannabinoid therapies for rare neuropsychiatric disorders. Their focus on pharmaceutically-produced cannabidiol, delivered via a permeation-enhanced gel, differentiates them within the competitive specialty drug market, addressing unmet needs in targeted patient populations.

What Is the Investment Thesis for ZYNE?

Zynerba Pharmaceuticals presents a high-risk, high-reward investment opportunity within the specialty pharmaceutical sector. The company's focus on transdermal cannabinoid therapies for rare neuropsychiatric disorders offers the potential for significant revenue generation if Zygel receives regulatory approval and achieves commercial success. Key value drivers include the successful completion of ongoing clinical trials, positive efficacy and safety data, and strategic partnerships for manufacturing and distribution. The company's market capitalization of $70.1M reflects the inherent risks associated with clinical-stage pharmaceutical companies, including regulatory hurdles and competition from established players. A successful FDA approval for Zygel could lead to a substantial increase in the company's valuation. However, potential investors should carefully consider the risks associated with clinical trial outcomes and the evolving regulatory landscape for cannabinoid-based therapies.

Based on FMP financials and quantitative analysis

ZYNE Key Highlights

Zynerba Pharmaceuticals is a clinical-stage company focused on rare neuropsychiatric disorders.

• The company's lead product candidate, Zygel, is a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery.
• Zynerba's focus on transdermal delivery aims to provide consistent and controlled drug administration.
• The company operates with a lean structure, employing approximately 25 individuals.
• Zynerba's market capitalization is $0.07 billion.

Who Are ZYNE's Competitors?

ZYNE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ZYNE's Key Strengths?

Proprietary transdermal delivery technology for cannabinoids.

• Focus on rare and near-rare neuropsychiatric disorders with unmet needs.
• Lead product candidate, Zygel, in clinical development.
• Experienced management team with expertise in pharmaceutical development.

What Are ZYNE's Weaknesses?

Clinical-stage company with no currently approved products.

• Limited financial resources and dependence on external funding.
• High risk of clinical trial failure.
• Competition from established pharmaceutical companies and other biotech firms.

What Could Drive ZYNE Stock Higher?

Data readouts from ongoing clinical trials of Zygel.

• Potential regulatory submissions for Zygel in targeted indications.
• Progress in securing strategic partnerships for manufacturing and distribution.
• Advancements in intellectual property protection for Zynerba's technologies.

What Are the Key Risks for ZYNE?

Financial-distress signal — its Altman Z-Score of -8.87 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-59.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory setbacks or rejection of Zygel.
• Competition from other companies developing similar therapies.
• Dependence on external funding and limited financial resources.
• Evolving regulatory landscape for cannabinoid-based therapies.

What Are the Growth Opportunities for ZYNE?

• Successful Clinical Trial Outcomes: Zynerba's most significant growth opportunity lies in the successful completion of ongoing clinical trials for Zygel. Positive data demonstrating efficacy and safety in treating rare neuropsychiatric disorders would significantly de-risk the company and increase its attractiveness to potential partners and investors. The timeline for this growth driver is dependent on the progression of clinical trials, with potential data readouts expected over the next 12-24 months. The market size for targeted indications could reach hundreds of millions of dollars annually.
• Regulatory Approval and Commercialization: Obtaining regulatory approval from the FDA or other regulatory agencies is crucial for Zynerba's long-term growth. Approval would allow the company to commercialize Zygel and generate revenue from sales. The timeline for this growth driver is dependent on the clinical trial outcomes and the regulatory review process, which typically takes 12-18 months after submission. The market size for approved indications could be substantial, particularly if Zygel addresses a significant unmet need.
• Strategic Partnerships and Collaborations: Zynerba can accelerate its growth by forming strategic partnerships with larger pharmaceutical companies for manufacturing, distribution, or co-development of Zygel. These partnerships can provide access to resources, expertise, and established commercial infrastructure. The timeline for this growth driver is uncertain but could occur at any point in the near future. The potential impact on market reach and revenue generation could be significant.
• Expansion into New Indications: Zynerba can expand its product pipeline by exploring the potential of Zygel or other cannabinoid-based therapies in treating additional neuropsychiatric disorders. This would require further research and development efforts, but could significantly increase the company's long-term growth potential. The timeline for this growth driver is dependent on the availability of resources and the success of initial research. The market size for new indications could be substantial.
• Intellectual Property Protection: Strengthening its intellectual property portfolio through patents and other forms of protection is crucial for Zynerba's competitive advantage. Strong IP protection can prevent competitors from developing similar products and ensure that Zynerba retains exclusive rights to its cannabinoid-based therapies. The timeline for this growth driver is ongoing, as the company continues to pursue new patent applications. The value of intellectual property protection is significant in the pharmaceutical industry.

What Threats Does ZYNE Face?

• Regulatory hurdles and changing regulations for cannabinoid-based therapies.
• Competition from other companies developing similar therapies.
• Potential for adverse events or safety concerns in clinical trials.
• Difficulty in raising capital to fund ongoing research and development.

What Are ZYNE's Competitive Advantages?

• Proprietary transdermal delivery technology.
• Focus on rare and near-rare diseases with unmet medical needs.
• Intellectual property protection through patents.
• First-mover advantage in developing pharmaceutically-produced transdermal cannabinoid therapies.

What Does ZYNE Do?

Zynerba Pharmaceuticals, Inc., founded in 2007 and headquartered in Devon, Pennsylvania, is a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal cannabinoid therapies. Originally incorporated as AllTranz, Inc., the company rebranded as Zynerba Pharmaceuticals in August 2014, signaling a strategic shift towards cannabinoid-based therapeutics. The company's primary focus is on addressing the unmet needs of patients with rare and near-rare neuropsychiatric disorders. Their lead product candidate, Zygel, is a pharmaceutically-produced cannabidiol (CBD) formulated as a permeation-enhanced gel designed for transdermal delivery. This method aims to provide consistent and controlled drug delivery, potentially improving patient outcomes and reducing side effects compared to traditional oral or inhaled routes of administration. Zynerba's research and development efforts are centered on leveraging the therapeutic potential of cannabinoids while adhering to rigorous pharmaceutical standards. The company operates with a lean structure, employing approximately 25 individuals, and is focused on advancing Zygel through clinical trials and navigating the regulatory approval process.

What Products and Services Does ZYNE Offer?

• Develops pharmaceutically-produced transdermal cannabinoid therapies.
• Focuses on rare and near-rare neuropsychiatric disorders.
• Formulates cannabidiol (CBD) as a permeation-enhanced gel for transdermal delivery.
• Conducts clinical trials to evaluate the efficacy and safety of its therapies.
• Seeks regulatory approval from the FDA and other agencies.
• Aims to commercialize its therapies and generate revenue from sales.

How Does ZYNE Make Money?

• Develops and patents novel transdermal cannabinoid formulations.
• Conducts clinical trials to demonstrate efficacy and safety.
• Seeks regulatory approval to market and sell its products.
• Potentially partners with larger pharmaceutical companies for manufacturing and distribution.

What Industry Does ZYNE Operate In?

Zynerba Pharmaceuticals operates within the specialty pharmaceutical industry, a segment characterized by its focus on developing and marketing niche therapies for specific patient populations. The industry is driven by innovation, with companies constantly seeking to address unmet medical needs. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms. Zynerba's focus on cannabinoid-based therapies places it within a rapidly evolving segment of the market, driven by increasing acceptance of medical cannabis and ongoing research into the therapeutic potential of cannabinoids. The global market for cannabinoid-based pharmaceuticals is projected to experience significant growth in the coming years, presenting both opportunities and challenges for companies like Zynerba.

Who Are ZYNE's Key Customers?

• Patients with rare and near-rare neuropsychiatric disorders.
• Physicians who treat these patients.
• Pharmacies that dispense prescription medications.
• Potentially, hospitals and other healthcare institutions.

Company Profile

Zynerba Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Devon, US. The company is led by CEO Armando Anido MBA. ZYNE has traded publicly since 2015.

Zynerba Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.87 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Zynerba Pharmaceuticals, Inc. stands at -59.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -62.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -33.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.97 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -62.8%, the inverse of the P/E and a quick read on earnings relative to price.

ZYNE Valuation & Market Position

With a $70.1M market cap, Zynerba Pharmaceuticals, Inc. sits in the micro-cap segment of the market.

The most recent 12 insider filings for Zynerba Pharmaceuticals, Inc. break down as 10 sales and 2 purchases. On net that is roughly 792K shares disposed (about $624K), a signal worth weighing alongside the fundamentals.

ZYNE Financials

ZYNE Latest News

No recent news available for ZYNE.

ZYNE Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources